Nautilus Biotechnology (NAUT) Enterprise Value (2020 - 2026)

Nautilus Biotechnology has disclosed Enterprise Value across 7 years of filings, most recently posting -$95.9 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$95.9 million, up 30.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$95.9 million (up 30.94% YoY), and the FY2025 annual result was -$103.4 million, up 20.39% from the prior year.
• Enterprise Value came in at -$95.9 million for Q1 2026 at Nautilus Biotechnology, up from -$103.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$95.9 million in Q1 2026 to a low of -$324.1 million in Q1 2022.
• The 5-year median for Enterprise Value is -$167.3 million (2023), against an average of -$175.9 million.
• Across the five-year window, Enterprise Value sank 47423.79% in 2022 and jumped 48.37% in 2023, its largest moves.
• Nautilus Biotechnology's Enterprise Value stood at -$184.5 million in 2022, then climbed by 5.99% to -$173.4 million in 2023, then rose by 25.1% to -$129.9 million in 2024, then grew by 20.39% to -$103.4 million in 2025, then increased by 7.29% to -$95.9 million in 2026.
• The last three Enterprise Value figures came in at -$95.9 million (Q1 2026), -$103.4 million (Q4 2025), and -$131.4 million (Q3 2025), per Business Quant data.